Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems (ELITE)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2013 by Cordis Corporation.
Recruitment status was:  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Cordis Corporation
ClinicalTrials.gov Identifier:
NCT00715884
First received: July 11, 2008
Last updated: December 17, 2013
Last verified: December 2013
Results First Received: February 25, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Subject);   Primary Purpose: Treatment
Conditions: Coronary Artery Disease
Coronary Atherosclerosis
Interventions: Device: CYPHER® ELITE™ Sirolimus-Eluting Stent System
Device: CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
ELITE™ CYPHER® ELITE™ Sirolimus-Eluting Stent System.
CYPHER® CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System

Participant Flow:   Overall Study
    ELITE™   CYPHER®
STARTED   452   226 
COMPLETED   444   225 
NOT COMPLETED   8   1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
ELITE™ CYPHER® ELITE™ Sirolimus-Eluting Stent System.
CYPHER® CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System
Total Total of all reporting groups

Baseline Measures
   ELITE™   CYPHER®   Total 
Overall Participants Analyzed 
[Units: Participants]
 452   226   678 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   252   137   389 
>=65 years   200   89   289 
Age 
[Units: Years]
Mean (Standard Deviation)
 63.1  (10.5)   62.2  (10.5)   62.8  (10.5) 
Gender 
[Units: Participants]
     
Female   138   74   212 
Male   314   152   466 
Ethnicity (NIH/OMB) 
[Units: Participants]
     
Hispanic or Latino   21   4   25 
Not Hispanic or Latino   421   218   639 
Unknown or Not Reported   10   4   14 
Region of Enrollment 
[Units: Participants]
     
United States   452   226   678 
Race 
[Units: Participants]
     
American Indian or Alaska Native   2   0   2 
Asian   11   3   14 
Native Hawaiian or Other Pacific Islander   0   0   0 
Black or African American   33   20   53 
White   403   203   606 
Other   3   0   3 
Patients with History of Previous Percutaneous Coronary Intervention (PCI) 
[Units: Participants]
     
History of Previous PCI   145   69   214 
Without History of Previous PCI   307   157   464 
Patients with History of Previous Coronary Artery Bypass Graft (CABG) 
[Units: Participants]
     
History of Previous CABG   48   21   69 
Without History of Previous CABG   404   205   609 
Patients with Family History of Coronary Artery (CAD) 
[Units: Participants]
     
Family History of Coronary Artery (CAD)   255   137   392 
Without Family History of Coronary Artery (CAD)   197   89   286 
Patients with History of Hyperlipidemia 
[Units: Participants]
     
History of Hyperlipidemia   388   188   576 
Without History of Hyperlipidemia   64   38   102 
Patients with History of Hypertension 
[Units: Participants]
     
History of Hypertension   360   178   538 
Without History of Hypertension   92   48   140 
Patients with History of Diabetes Mellitus 
[Units: Participants]
     
History of Diabetes Mellitus   144   69   213 
Without History of Diabetes Mellitus   308   157   465 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants Who Experienced Target Lesion Failure (TLF)   [ Time Frame: 12-months post-procedure ]

2.  Secondary:   Percentage of Lesion Success   [ Time Frame: At procedure ]

3.  Secondary:   Percentage of Device Success - Protocol Definition   [ Time Frame: At procedure ]

4.  Secondary:   Percentage of Device Success - All CYPHER® Stents Included   [ Time Frame: At procedure ]

5.  Secondary:   Percentage of Participants Who Achieved Procedure Success   [ Time Frame: At procedure during hospital stay ]

6.  Secondary:   Percentage of Participants Who Experienced Target Lesion Revascularization (TLR)   [ Time Frame: 12 months post-procedure ]

7.  Secondary:   Percentage of Participants Who Experienced Target Vessel Revascularization (TVR)   [ Time Frame: 12 months post procedure ]

8.  Secondary:   Percentage of Participants Who Experienced Target Vessel Failure (TVF)   [ Time Frame: 12 months post procedure ]

9.  Secondary:   Percentage of Participants Who Experienced Major Adverse Cardiac Events (MACE)   [ Time Frame: 12 months post procedure ]

10.  Secondary:   Percentage of Participants Who Had Lesions of More Than 1 Vessel and Experienced Target Lesion Failure (TLF)   [ Time Frame: 12 months post procedure ]

11.  Secondary:   Percentage of Participants Who Had Diabetes and Experienced Target Lesion Failure (TLF)   [ Time Frame: 12 months post procedure ]

12.  Secondary:   Percentage of Participants Who Experienced Bleeding Complications   [ Time Frame: 12 months post procedure ]

13.  Secondary:   Percentage of Participants Who Died   [ Time Frame: 12 months post procedure ]

14.  Secondary:   Percentage of Participants Who Experienced Any Myocardial Infarction (MI)   [ Time Frame: 12 months post procedure ]

15.  Secondary:   Percentage of Participants Who Experienced Stroke   [ Time Frame: 12 months post procedure ]

16.  Secondary:   Percentage of Participants Who Experienced Stent Thrombosis (Protocol Definition)   [ Time Frame: 12 months post procedure ]

17.  Secondary:   Percentage of Participants Who Experienced Stent Thrombosis (Academic Research Consortium (ARC) Definition)   [ Time Frame: 12 months post procedure ]

18.  Secondary:   Percentage of Participants Who Experienced Early Stent Thrombosis (Academic Research Consortium (ARC) Definition)   [ Time Frame: 0-30 days post-procedure ]

19.  Secondary:   Percentage of Participants Who Experienced Late Stent Thrombosis (Academic Research Consortium (ARC) Definition)   [ Time Frame: 31-360 days post-procedure ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The study was terminated early by the Sponsor for business reasons. Hence the data was under powered for hypothesis testing. No definitive conclusions can be made from this data.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Amy Orlick, Associate Director Clinical Research
Organization: Cordis
phone: 908-541-4347
e-mail: AOrlick@its.jnj.com



Responsible Party: Cordis Corporation
ClinicalTrials.gov Identifier: NCT00715884     History of Changes
Other Study ID Numbers: P07-6330
Study First Received: July 11, 2008
Results First Received: February 25, 2011
Last Updated: December 17, 2013
Health Authority: United States: Food and Drug Administration